Bristol-Myers Squibb (BMY) Crosses Pivot Point Support at $31.45 Financial News Network Online The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders. Potential upside of 6.5% exists for Bristol-Myers Squibb, ... |
